Investors

Keep up to date with all our latest financial information and events, and access our archives for historical data, presentations, statements and reports.

Latest results

Portfolio metrics

35+
Approved products
17
Development-stage therapies
15
Blockbuster products (>$1bn in annual sales)
~13year
Portfolio duration

Financial metrics

$3.0bn
Portfolio Receipts
(2023)
$2.8bn
Adjusted EBITDA
(2023)
$2.0bn
Average annual capital deployed (2018-2023)
$4.0bn
Announced value of transactions (2023)

Corporate presentation

SEC filings

Filing Date Form View
Loading…
All Filings

Latest releases

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

NEW YORK, NY and SOUTH SAN FRANCISCO, CA, May 22, 2024 – Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business.

Stay up to date

Subscribe to Royalty Pharma news and alerts

Subscribe